Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia
Leukemia, 06/04/2012
Clinical Article
Stone RM et al. – Midostaurin in combination with standard chemotherapy demonstrated high complete response and overall survival (OS) rates in newly diagnosed younger adults with acute myeloid leukemia (AML), and was generally well tolerated at 50mg twice daily for 14 days.



